- Home
- ATAI vs LIEN Comparison
ATAI vs LIEN Comparison
Compare ATAI & LIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- LIEN
- Stock Information
- Founded
- ATAI 2018
- LIEN 2021
- Country
- ATAI Germany
- LIEN United States
- Employees
- ATAI N/A
- LIEN N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- LIEN
- Sector
- ATAI Health Care
- LIEN
- Exchange
- ATAI Nasdaq
- LIEN NYSE
- Market Cap
- ATAI 282.6M
- LIEN 234.6M
- IPO Year
- ATAI 2021
- LIEN 2022
- Fundamental
- Price
- ATAI $1.41
- LIEN $10.10
- Analyst Decision
- ATAI Strong Buy
- LIEN Hold
- Analyst Count
- ATAI 3
- LIEN 1
- Target Price
- ATAI $10.50
- LIEN N/A
- AVG Volume (30 Days)
- ATAI 1.4M
- LIEN 16.8K
- Earning Date
- ATAI 05-19-2025
- LIEN 05-14-2025
- Dividend Yield
- ATAI N/A
- LIEN 13.59%
- EPS Growth
- ATAI N/A
- LIEN N/A
- EPS
- ATAI N/A
- LIEN 0.93
- Revenue
- ATAI $308,000.00
- LIEN $21,665,753.00
- Revenue This Year
- ATAI $65.58
- LIEN $102.44
- Revenue Next Year
- ATAI N/A
- LIEN N/A
- P/E Ratio
- ATAI N/A
- LIEN $10.77
- Revenue Growth
- ATAI N/A
- LIEN 81.56
- 52 Week Low
- ATAI $1.03
- LIEN $9.71
- 52 Week High
- ATAI $2.57
- LIEN $13.38
- Technical
- Relative Strength Index (RSI)
- ATAI 44.57
- LIEN N/A
- Support Level
- ATAI $1.36
- LIEN N/A
- Resistance Level
- ATAI $1.54
- LIEN N/A
- Average True Range (ATR)
- ATAI 0.09
- LIEN 0.00
- MACD
- ATAI -0.00
- LIEN 0.00
- Stochastic Oscillator
- ATAI 0.00
- LIEN 0.00
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About LIEN CHICAGO ATLANTIC BDC INC
Chicago Atlantic BDC Inc is a specialty finance company. The company is an externally managed, closed-end, non-diversified management investment company with an investment objective to maximize risk-adjusted returns on equity for its stockholders by investing in direct loans to privately held middle-market companies, with a focus on cannabis companies.